1. Report Introduction 2. Neurofibromatosis 2 Market Overview at a Glance 2.1. Market Share Distribution of Neurofibromatosis 2 in 2018 2.2. Market Share Distribution of Neurofibromatosis 2 in 2028 3. Disease Background and Overview: Neurofibromatosis 2 3.1. Introduction 3.2. Symptoms 3.3. Etiology 3.4. Risk Factors 3.5. Pathophysiology 3.6. Diagnosis 3.7. Treatment 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Prevalent/ Incident Patient Population of Neurofibromatosis 2 in 7MM 4.3. Total Prevalent Patient Population of Neurofibromatosis 2 in 7MM – By Countries 5. Epidemiology of Neurofibromatosis 2 by Countries 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Prevalent/Incident Cases of the Neurofibromatosis 2 5.1.3. Sub-Type Specific cases of the Neurofibromatosis 2 *Indication Specific 5.1.4. Sex- Specific Cases of the Neurofibromatosis 2*Indication Specific 5.1.5. Diagnosed Cases of the Neurofibromatosis 2 5.1.6. Treatable Cases of the Neurofibromatosis 2 5.2. EU5 5.3. Assumptions and Rationale 5.4. Germany 5.4.1. Assumptions and Rationale 5.4.2. Prevalent/Incident Cases of the Neurofibromatosis 2 5.4.3. Sub-Type Specific cases of the Neurofibromatosis 2* 5.4.4. Sex- Specific Cases of the Neurofibromatosis 2* 5.4.5. Diagnosed Cases of the Neurofibromatosis 2 5.4.6. Treatable Cases of the Neurofibromatosis 2 5.5. France 5.5.1. Assumptions and Rationale 5.5.2. Prevalent/Incident Cases of the Neurofibromatosis 2 5.5.3. Sub-Type Specific cases of the Neurofibromatosis 2* 5.5.4. Sex- Specific Cases of the Neurofibromatosis 2* 5.5.5. Diagnosed Cases of the Neurofibromatosis 2 5.5.6. Treatable Cases of the Neurofibromatosis 2 5.6. Italy 5.6.1. Assumptions and Rationale 5.6.2. Prevalent/Incident Cases of the Neurofibromatosis 2 5.6.3. Sub-Type Specific cases of the Neurofibromatosis 2* 5.6.4. Sex- Specific Cases of the Neurofibromatosis 2* 5.6.5. Diagnosed Cases of the Neurofibromatosis 2 5.6.6. Treatable Cases of the Neurofibromatosis 2 5.7. Spain 5.7.1. Assumptions and Rationale 5.7.2. Prevalent/Incident Cases of the Neurofibromatosis 2 5.7.3. Sub-Type Specific cases of the Neurofibromatosis 2* 5.7.4. Sex- Specific Cases of the Neurofibromatosis 2* 5.7.5. Diagnosed Cases of the Neurofibromatosis 2 5.7.6. Treatable Cases of the Neurofibromatosis 2 5.8. United Kingdom 5.8.1. Assumptions and Rationale 5.8.2. Prevalent/Incident Cases of the Neurofibromatosis 2 5.8.3. Sub-Type Specific cases of the Neurofibromatosis 2* 5.8.4. Sex- Specific Cases of the Neurofibromatosis 2* 5.8.5. Diagnosed Cases of the Neurofibromatosis 2 5.8.6. Treatable Cases of the Neurofibromatosis 2 5.9. Japan 5.9.1. Assumptions and Rationale 5.9.2. Prevalent/Incident Cases of the Neurofibromatosis 2 5.9.3. Sub-Type Specific cases of the Neurofibromatosis 2* 5.9.4. Sex- Specific Cases of the Neurofibromatosis 2* 5.9.5. Diagnosed Cases of the Neurofibromatosis 2 5.9.6. Treatable Cases of the Neurofibromatosis 2 6. Current Treatment & Medical practices 6.1. Treatment Algorithm 6.2. Treatment Guidelines 7. Unmet Needs of the Neurofibromatosis 2 8. Marketed Therapies 8.1. Drug A: Company 1 8.1.1. Drug Description 8.1.2. Mechanism of Action 8.1.3. Regulatory Milestones 8.1.4. Advantages & Disadvantages 8.1.5. Product Profile 8.2. Drug B: Company 2 8.2.1. Drug Description 8.2.2. Mechanism of Action 8.2.3. Regulatory Milestones 8.2.4. Advantages & Disadvantages 8.2.5. Product Profile 9. Pipeline Therapies – At a glance 10. Key Cross Competition 11. Emerging Therapies for Neurofibromatosis 2 11.1. Drug C: Company 3 11.1.1. Drug Description 11.1.2. Clinical Trials Details 11.1.3. Safety and Efficacy Profile 11.1.4. Advantages & Disadvantages 11.1.5. Pipeline Development Activities 11.1.6. Product Profile 11.2. Drug D: Company 4 11.2.1. Drug Description 11.2.2. Clinical Trials Details 11.2.3. Safety and Efficacy Profile 11.2.4. Advantages & Disadvantages 11.2.5. Pipeline Development Activities 11.2.6. Product Profile 12. Neurofibromatosis 2: 7MM Market Analysis 12.1. 7MM Market Size of Neurofibromatosis 2 12.2. 7MM Percentage Share of drugs marketed for Neurofibromatosis 2 12.3. 7MM Market Sales of Neurofibromatosis 2 by Products 13. Neurofibromatosis 2: Country-Wise Market Analysis 13.1. United States 13.1.1. Market Size of Neurofibromatosis 2 in United States 13.1.2. Percentage Share of drugs marketed for Neurofibromatosis 2 in United States 13.1.3. Market Sales of Neurofibromatosis 2 by Products in United States 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2. EU-5 13.2.1. Germany 13.2.1.1. Market Size of Neurofibromatosis 2 in Germany 13.2.1.2. Percentage Share of drugs marketed for Neurofibromatosis 2 in Germany 13.2.1.3. Market Sales of Neurofibromatosis 2 by Products in Germany 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.2. France 13.2.2.1. Market Size of Neurofibromatosis 2 in France 13.2.2.2. Percentage Share of drugs marketed for Neurofibromatosis 2 in France 13.2.2.3. Market Sales of Neurofibromatosis 2 by Products in France 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.3. Italy 13.2.3.1. Market Size of Neurofibromatosis 2 in Italy 13.2.3.2. Percentage Share of drugs marketed for Neurofibromatosis 2 in Italy 13.2.3.3. Market Sales of Neurofibromatosis 2 by Products in Italy 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.4. Spain 13.2.4.1. Market Size of Neurofibromatosis 2 in Spain 13.2.4.2. Percentage Share of drugs marketed for Neurofibromatosis 2 in Spain 13.2.4.3. Market Sales of Neurofibromatosis 2 by Products in Spain 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.5. United Kingdom 13.2.5.1. Market Size of Neurofibromatosis 2 in United Kingdom 13.2.5.2. Percentage Share of drugs marketed for Neurofibromatosis 2 in United Kingdom 13.2.5.3. Market Sales of Neurofibromatosis 2 by Products in United Kingdom 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market 13.3. Japan 13.3.1. Market Size of Neurofibromatosis 2 in Japan 13.3.2. Percentage Share of drugs marketed for Neurofibromatosis 2 in Japan 13.3.3. Market Sales of Neurofibromatosis 2 by Products in Japan 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market 14. Market Drivers 15. Market Barriers 16. Appendix 17. Report Methodology 17.1. Sources 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight

Table 1: Total Prevalent/Incident Cases of the Neurofibromatosis 2 in 7MM Table 2: Total Prevalent/Incident Cases of the Neurofibromatosis 2 in 7MM by Countries Table 3: Prevalent/Incident Cases of the Neurofibromatosis 2 in United States (2017-2028) Table 4: Sub-Type Specific cases of the Neurofibromatosis 2 in United States (2017-2028) Table 5: Sex- Specific Cases of the Neurofibromatosis 2 in United States (2017-2028) Table 6: Diagnosed Cases of the Neurofibromatosis 2 in United States (2017-2028) Table 7: Treatable Cases of the Neurofibromatosis 2 in United States (2017-2028) Table 8: Prevalent/Incident Cases of the Neurofibromatosis 2 in Germany (2017-2028) Table 9: Sub-Type Specific cases of the Neurofibromatosis 2 in Germany (2017-2028) Table 10: Sex- Specific Cases of the Neurofibromatosis 2 in Germany (2017-2028) Table 11: Diagnosed Cases of the Neurofibromatosis 2 in Germany (2017-2028) Table 12: Treatable Cases of the Neurofibromatosis 2 in Germany (2017-2028) Table 13: Prevalent/Incident Cases of the Neurofibromatosis 2 in France (2017-2028) Table 14: Sub-Type Specific cases of the Neurofibromatosis 2 in France (2017-2028) Table 15: Sex- Specific Cases of the Neurofibromatosis 2 in France (2017-2028) Table 16: Diagnosed Cases of the Neurofibromatosis 2 in France (2017-2028) Table 17: Treatable Cases of the Neurofibromatosis 2 in France (2017-2028) Table 18: Prevalent/Incident Cases of the Neurofibromatosis 2 in Italy (2017-2028) Table 19: Sub-Type Specific cases of the Neurofibromatosis 2 in Italy (2017-2028) Table 20: Sex- Specific Cases of the Neurofibromatosis 2 in Italy (2017-2028) Table 21: Diagnosed Cases of the Neurofibromatosis 2 in Italy (2017-2028) Table 22: Treatable Cases of the Neurofibromatosis 2 in Italy (2017-2028) Table 23: Prevalent/Incident Cases of the Neurofibromatosis 2 in Spain (2017-2028) Table 24: Sub-Type Specific cases of the Neurofibromatosis 2 in Spain (2017-2028) Table 25: Sex- Specific Cases of the Neurofibromatosis 2 in Spain (2017-2028) Table 26: Diagnosed Cases of the Neurofibromatosis 2 in Spain (2017-2028) Table 27: Treatable Cases of the Neurofibromatosis 2 in Spain (2017-2028) Table 28: Prevalent/Incident Cases of the Neurofibromatosis 2 in UK (2017-2028) Table 29: Sub-Type Specific cases of the Neurofibromatosis 2 in UK (2017-2028) Table 30: Sex- Specific Cases of the Neurofibromatosis 2 in UK (2017-2028) Table 31: Diagnosed Cases of the Neurofibromatosis 2 in UK (2017-2028) Table 32: Treatable Cases of the Neurofibromatosis 2 in UK (2017-2028) Table 33: Prevalent/Incident Cases of the Neurofibromatosis 2 in Japan (2017-2028) Table 34: Sub-Type Specific cases of the Neurofibromatosis 2 in Japan (2017-2028) Table 35: Sex- Specific Cases of the Neurofibromatosis 2 in Japan (2017-2028) Table 36: Diagnosed Cases of the Neurofibromatosis 2 in Japan (2017-2028) Table 37: Treatable Cases of the Neurofibromatosis 2 in Japan (2017-2028) Table 38: Marketed Therapies Table 39: Emerging Therapies Table 40: Key Cross Competition Table 41:7MM- Market Size of Neurofibromatosis 2 in USD MM (2017-2028) Table 42:7MM- Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Table 43:7MM- Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Table 44: United States-Market Size of Neurofibromatosis 2 in USD MM (2017-2028) Table 45: United States-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Table 46: United States-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Table 47: Germany-Market Size of Neurofibromatosis 2 in USD MM (2017-2028) Table 48: Germany-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Table 49: Germany-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Table 50: France-Market Size of Neurofibromatosis 2 in USD MM (2017-2028) Table 51: France-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Table 52: France-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Table 53: Italy-Market Size of Neurofibromatosis 2 in USD MM (2017-2028) Table 54: Italy-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Table 55: Italy-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Table 56: Spain-Market Size of Neurofibromatosis 2 in USD MM (2017-2028) Table 57: Spain-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Table 58: Spain-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Table 59:UK-Market Size of Neurofibromatosis 2 in USD MM (2017-2028) Table 60:UK-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Table 61:UK-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Table 62: Japan-Market Size of Neurofibromatosis 2 in USD MM (2017-2028) Table 63: Japan-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Table 64: Japan-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Figure 1: Total Prevalent/Incident Cases of the Neurofibromatosis 2 in 7MM Figure 2: Total Prevalent/Incident Cases of the Neurofibromatosis 2 in 7MM by Countries Figure 3: Prevalent/Incident Cases of the Neurofibromatosis 2 in United States (2017-2028) Figure 4: Sub-Type Specific cases of the Neurofibromatosis 2 in United States (2017-2028) Figure 5: Sex- Specific Cases of the Neurofibromatosis 2 in United States (2017-2028) Figure 6: Diagnosed Cases of the Neurofibromatosis 2 in United States (2017-2028) Figure 7: Treatable Cases of the Neurofibromatosis 2 in United States (2017-2028) Figure 8: Prevalent/Incident Cases of the Neurofibromatosis 2 in Germany (2017-2028) Figure 9: Sub-Type Specific cases of the Neurofibromatosis 2 in Germany (2017-2028) Figure 10: Sex- Specific Cases of the Neurofibromatosis 2 in Germany (2017-2028) Figure 11: Diagnosed Cases of the Neurofibromatosis 2 in Germany (2017-2028) Figure 12: Treatable Cases of the Neurofibromatosis 2 in Germany (2017-2028) Figure 13: Prevalent/Incident Cases of the Neurofibromatosis 2 in France (2017-2028) Figure 14: Sub-Type Specific cases of the Neurofibromatosis 2 in France (2017-2028) Figure 15: Sex- Specific Cases of the Neurofibromatosis 2 in France (2017-2028) Figure 16: Diagnosed Cases of the Neurofibromatosis 2 in France (2017-2028) Figure 17: Treatable Cases of the Neurofibromatosis 2 in France (2017-2028) Figure 18: Prevalent/Incident Cases of the Neurofibromatosis 2 in Italy (2017-2028) Figure 19: Sub-Type Specific cases of the Neurofibromatosis 2 in Italy (2017-2028) Figure 20: Sex- Specific Cases of the Neurofibromatosis 2 in Italy (2017-2028) Figure 21: Diagnosed Cases of the Neurofibromatosis 2 in Italy (2017-2028) Figure 22: Treatable Cases of the Neurofibromatosis 2 in Italy (2017-2028) Figure 23: Prevalent/Incident Cases of the Neurofibromatosis 2 in Spain (2017-2028) Figure 24: Sub-Type Specific cases of the Neurofibromatosis 2 in Spain (2017-2028) Figure 25: Sex- Specific Cases of the Neurofibromatosis 2 in Spain (2017-2028) Figure 26: Diagnosed Cases of the Neurofibromatosis 2 in Spain (2017-2028) Figure 27: Treatable Cases of the Neurofibromatosis 2 in Spain (2017-2028) Figure 28: Prevalent/Incident Cases of the Neurofibromatosis 2 in UK (2017-2028) Figure 29: Sub-Type Specific cases of the Neurofibromatosis 2 in UK (2017-2028) Figure 30: Sex- Specific Cases of the Neurofibromatosis 2 in UK (2017-2028) Figure 31: Diagnosed Cases of the Neurofibromatosis 2 in UK (2017-2028) Figure 32: Treatable Cases of the Neurofibromatosis 2 in UK (2017-2028) Figure 33: Prevalent/Incident Cases of the Neurofibromatosis 2 in Japan (2017-2028) Figure 34: Sub-Type Specific cases of the Neurofibromatosis 2 in Japan (2017-2028) Figure 35: Sex- Specific Cases of the Neurofibromatosis 2 in Japan (2017-2028) Figure 36: Diagnosed Cases of the Neurofibromatosis 2 in Japan (2017-2028) Figure 37: Treatable Cases of the Neurofibromatosis 2 in Japan (2017-2028) Figure 38: Marketed Therapies Figure 39: Emerging Therapies Figure 40: Key Cross Competition Figure 41:7MM- Market Size of Neurofibromatosis 2 in USD MM (2017-2028) Figure 42:7MM- Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Figure 43:7MM- Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Figure 44: United States-Market Size of Neurofibromatosis 2 in USD MM (2017-2028) Figure 45: United States-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Figure 46: United States-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Figure 47: Germany-Market Size of Neurofibromatosis 2 in USD MM (2017-2028) Figure 48: Germany-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Figure 49: Germany-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Figure 50: France-Market Size of Neurofibromatosis 2 in USD MM (2017-2028) Figure 51: France-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Figure 52: France-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Figure 53: Italy-Market Size of Neurofibromatosis 2 in USD MM (2017-2028) Figure 54: Italy-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Figure 55: Italy-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Figure 56: Spain-Market Size of Neurofibromatosis 2 in USD MM (2017-2028) Figure 57: Spain-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Figure 58: Spain-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Figure 59:UK-Market Size of Neurofibromatosis 2 in USD MM (2017-2028) Figure 60:UK-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Figure 61:UK-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Figure 62: Japan-Market Size of Neurofibromatosis 2 in USD MM (2017-2028) Figure 63: Japan-Market Share Neurofibromatosis 2 by Therapies in USD MM (2017-2028) Figure 64: Japan-Market Sales of Neurofibromatosis 2 by Therapies in USD MM (2017-2028)